ARTICLE
14 January 2020

What Next For The UK's Cannabis Laws? – John Binns For Open Access Government

BS
BCL Solicitors LLP

Contributor

BCL Solicitors is a law firm with a single-minded ambition – to achieve the best possible outcome for each and every client. We specialise in corporate and financial crime, regulatory enforcement and serious and general crime. We offer discreet, effective and expert advice to corporations, senior executives, public bodies and high-profile individuals.
BCL partner John Binns writes for Open Access Government on the future developments UK legal cannabis industry, including legal, cultural and political challenges.
United Kingdom Cannabis & Hemp

BCL partner John Binns writes for Open Access Government on the future developments UK legal cannabis industry, including legal, cultural and political challenges.

Here's an extract from the article:

"The first set of challenges brought by UK law to the cannabis debate are technical in nature, arising simply from the way our laws are written. One key topical example is the fact that, contrary to much public reporting on the subject, our Misuse of Drugs Act contains no exemption for products that contain THC below a certain minimum threshold (whether 0.2% or otherwise), causing a problem for many CBD products that contain such trace amounts. Another is that our Proceeds of Crime Act (POCA) prohibits virtually any dealing with the proceeds of 'criminal conduct', defined to include conduct that is lawful overseas but that would be unlawful if it happened here

On the face of it, these issues would be relatively easy to resolve, by amending the legislation to bring it in line with what most people would reasonably assume is the law – although any technical solution would itself bring technical questions. Would it, for instance, be for the producer or the retailer of the CBD product to prove that its THC content is below the relevant threshold? And should that threshold be put at 0.2%, or somewhere else? Would a POCA exemption cover all overseas drug sales or just medicinal cannabis from certain jurisdictions? And how would it address the relevance of U.S. federal law?

Such technical fixes would certainly be good for business, though it should be noted that on the one hand, there are already routes to operate within the existing law and on the other hand, that there are myriad other laws – on cosmetics labelling, on e-cigarettes, on food safety, on marketing of medical products – that serve to make the UK a highly regulated environment."

This article was originally published by Open Access Government. You can read the full article on their website.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More